Astrid Lièvre1, Jean-Louis Merlin2, Jean-Christophe Sabourin3, Pascal Artru4, Sabine Tong5, Lucie Libert5, François Audhuy6, Corinne Gicquel6, Laurence Moureau-Zabotto7, Roch-Anicet Ossendza8, Pierre Laurent-Puig9, Michel Ducreux10. 1. Department of Gastroenterology, CHU Pontchaillou, 2 Rue Henri le Guilloux, 35000 Rennes, France; University of Rennes 1, 2 Avenue du Professeur Léon Bernard, 35000 Rennes, France; INSERM U1242, Oncogenesis, Stress & Signaling, rue de la Bataille Flandres Dunkerque, 35000 Rennes, France. Electronic address: astrid.lievre@chu-rennes.fr. 2. University of Lorraine, 34 Cours Léopold, 54000 Nancy, France; CNRS UMR7039 CRAN, Boulevard des Aiguillettes, 54506 Vandoeuvre-lès-Nancy, France; Biopathology Department, Cancer Institute of Lorraine, 6 Avenue de Bourgogne, 54519 Vandoeuvre-lès-Nancy, France. 3. Pathology Department, CHU Charles Nicolle, 1 Rue de Germont, 76000 Rouen, France; Inserm 1079, University of Normandy, 22 Boulevard Gambetta, 76183 Rouen, France. 4. Department of Digestive Oncology, Jean Mermoz Hospital, 55 Avenue Jean Mermoz, 69008 Lyon, France. 5. Axonal, 215 Avenue Georges Clemenceau, 92000 Nanterre, France. 6. Merck Santé, 37 Rue Saint-Romain, 69008 Lyon, France. 7. Department of Radiotherapy, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, 13273 Marseille, France. 8. Department of Hepatogastroenterology, Chalons-en-Champagne Hospital, 51 Rue du Commandant Derrien, 51005 Chalons-en-Champagne, France. 9. UMRS-1174 Personnalized Medicine, Pharmacogenomic, Therapeutic Optimization; Paris Descartes University, 12 Rue de l'Ecole de Médecine, 75006 Paris, France; Department of Biology, Georges Pompidou European Hospital, 20 Rue Leblanc, 75015 Paris, France. 10. Department of Oncology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, Paris-Saclay University, France.
Abstract
BACKGROUND: RAS (NRAS + KRAS) mutation testing is required in addition to simple KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies (MAb) as in metastatic colorectal cancer (mCRC). AIMS: To assess prescription and implementation rates of RAS/KRAS mutation testing. To describe the RAS/KRAS mutation test procedure and its impact on therapeutic strategy. PATIENTS AND METHODS: Observational retrospective study conducted from June to September 2014 in all consecutive patients with newly diagnosed mCRC. RESULTS: Data from 375 patients (male: 57.8%; mean age, 65.7 ± 11.7 years) were analysed. RAS/KRAS mutation testing was prescribed in 90.1% of patients (338/375). The test was prescribed within 1 month around mCRC diagnosis and prior to first-line therapy in 73.1% (242/331) and 85.4% (280/328) of patients, respectively. Time from test request to receipt of results was 24.6 ± 17.2 days. 59.7% of patients (190/318) had a mutation, mainly KRAS (47.9%; 152/317). Anti-EGFR MAb was prescribed in 90.9% of RAS-wild-type cases (60/66), consistent with the goal of genotyping-testing in this population. CONCLUSION: In 2014, RAS genotyping-testing in addition to KRAS testing was routinely prescribed and performed in mCRC patients in France. Time to receive results remains long and must be reduced so as to match clinical practice.
BACKGROUND: RAS (NRAS + KRAS) mutation testing is required in addition to simple KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies (MAb) as in metastatic colorectal cancer (mCRC). AIMS: To assess prescription and implementation rates of RAS/KRAS mutation testing. To describe the RAS/KRAS mutation test procedure and its impact on therapeutic strategy. PATIENTS AND METHODS: Observational retrospective study conducted from June to September 2014 in all consecutive patients with newly diagnosed mCRC. RESULTS: Data from 375 patients (male: 57.8%; mean age, 65.7 ± 11.7 years) were analysed. RAS/KRAS mutation testing was prescribed in 90.1% of patients (338/375). The test was prescribed within 1 month around mCRC diagnosis and prior to first-line therapy in 73.1% (242/331) and 85.4% (280/328) of patients, respectively. Time from test request to receipt of results was 24.6 ± 17.2 days. 59.7% of patients (190/318) had a mutation, mainly KRAS (47.9%; 152/317). Anti-EGFR MAb was prescribed in 90.9% of RAS-wild-type cases (60/66), consistent with the goal of genotyping-testing in this population. CONCLUSION: In 2014, RAS genotyping-testing in addition to KRAS testing was routinely prescribed and performed in mCRC patients in France. Time to receive results remains long and must be reduced so as to match clinical practice.
Authors: Lola-Jade Palmieri; Tomas Buchler; Antoine Meyer; Veronika Veskrnova; Ondrej Fiala; Petr Brabec; Jana Baranova; Romain Coriat Journal: Cancers (Basel) Date: 2022-03-10 Impact factor: 6.639